282 related articles for article (PubMed ID: 12883702)
21. Clinical significance of double staining of MIB-1 and AgNORs in primary breast carcinoma.
Kidogawa H; Nanashima A; Yano H; Matsumoto M; Yasutake T; Nagayasu T
Anticancer Res; 2005; 25(6B):3957-62. PubMed ID: 16309183
[TBL] [Abstract][Full Text] [Related]
22. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters.
Sirotkovic-Skerlev M; Krizanac S; Kapitanovic S; Husnjak K; Unusic J; Pavelic K
Exp Mol Pathol; 2005 Aug; 79(1):42-50. PubMed ID: 16005711
[TBL] [Abstract][Full Text] [Related]
23. Role of the argyrophilic nucleolar organizer regions in tumor detection and prognosis.
Pich A; Chiusa L; Margaria E
Cancer Detect Prev; 1995; 19(3):282-91. PubMed ID: 7750118
[TBL] [Abstract][Full Text] [Related]
24. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast.
Selim AG; El-Ayat G; Wells CA
Virchows Arch; 2002 Nov; 441(5):449-55. PubMed ID: 12447674
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
26. Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support.
Hensel M; Schneeweiss A; Sinn HP; Egerer G; Kornacker M; Solomayer E; Haas R; Bastert G; Ho AD
Stem Cells; 2002; 20(1):32-40. PubMed ID: 11796920
[TBL] [Abstract][Full Text] [Related]
27. Cathepsin B, p53 expression and AgNORs in transitional cell carcinoma.
Akpolat I; Bariş YS; Yilmaz AF; Bakirtaş M; Saylik A; Karagöz F; Kandemir B
Neoplasma; 1998; 45(6):365-8. PubMed ID: 10210109
[TBL] [Abstract][Full Text] [Related]
28. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy.
Rau B; Sturm I; Lage H; Berger S; Schneider U; Hauptmann S; Wust P; Riess H; Schlag PM; Dörken B; Daniel PT
J Clin Oncol; 2003 Sep; 21(18):3391-401. PubMed ID: 12885834
[TBL] [Abstract][Full Text] [Related]
29. Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis.
Schiller AB; Clark WS; Cotsonis G; Lawson D; DeRose PB; Cohen C
Cytometry; 2002 Aug; 50(4):203-9. PubMed ID: 12210599
[TBL] [Abstract][Full Text] [Related]
30. [Significance of the AgNOR in tumor pathology].
Pich A; Margaria E; Chiusa L
Pathologica; 2002 Feb; 94(1):2-9. PubMed ID: 11912874
[TBL] [Abstract][Full Text] [Related]
31. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer.
Lipponen PK
J Pathol; 1995 Feb; 175(2):203-10. PubMed ID: 7738716
[TBL] [Abstract][Full Text] [Related]
32. Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast.
Zolota V; Gerokosta A; Melachrinou M; Kominea A; Aletra C; Scopa CD
Anticancer Res; 1999; 19(4B):3269-74. PubMed ID: 10652623
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
34. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder.
Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Navone R
Am J Surg Pathol; 2001 Dec; 25(12):1528-33. PubMed ID: 11717543
[TBL] [Abstract][Full Text] [Related]
35. The prognostic value of the AgNOR parameter in human breast cancer depends on the pRb and p53 status.
Derenzini M; Ceccarelli C; Santini D; Taffurelli M; Treré D
J Clin Pathol; 2004 Jul; 57(7):755-61. PubMed ID: 15220371
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women.
Talley L; Chhieng DC; Bell WC; Grizzle WE; Frost AR
Biotech Histochem; 2008 Feb; 83(1):5-14. PubMed ID: 18568671
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
[TBL] [Abstract][Full Text] [Related]
38. Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysis.
Bánkfalvi A; Giuffrè G; Ofner D; Diallo R; Poremba C; Buchwalow IB; Barresi V; Böcker W; Tuccari G
Int J Oncol; 2003 Nov; 23(5):1285-92. PubMed ID: 14532967
[TBL] [Abstract][Full Text] [Related]
39. DNA ploidy and p53 expression correlate with survival and cell proliferative activity in male breast carcinoma.
Pich A; Margaria E; Chiusa L; Ponti R; Geuna M
Hum Pathol; 1996 Jul; 27(7):676-82. PubMed ID: 8698311
[TBL] [Abstract][Full Text] [Related]
40. BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma.
Gonzalez-Campora R; Davalos-Casanova G; Beato-Moreno A; Garcia-Escudero A; Pareja Megia MJ; Montironi R; Lopez-Beltran A
Cancer Lett; 2007 Jun; 250(2):292-9. PubMed ID: 17126995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
